Cash Flow Statement

Amortization of Deferred Charges Amortizatization of Intangibles Asset Writedowns and Impairment Beginning Cash Balance Capital Expenditures Cash from Discontinued Operations Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Inventory Change in Net Loans Change in Receivables Change in Taxes Depreciation & Amortization (CF)Depreciation and Depletion Divestments Dividends Paid - Common Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Income Non-cash Items Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Fortress Biotech (FBIO) Acquisitions (2016 - 2023)

Fortress Biotech has reported Acquisitions over the past 6 years, most recently at -$5.0 million for Q1 2023.

Quarterly results put Acquisitions at -$5.0 million for Q1 2023, up 75.0% from a year ago — trailing twelve months through Jun 2024 was -$5.0 million (changed 0.0% YoY), and the annual figure for FY2022 was -$20.0 million, changed.
Acquisitions for Q1 2023 was -$5.0 million at Fortress Biotech, up from -$20.0 million in the prior quarter.
Over the last five years, Acquisitions for FBIO hit a ceiling of -$5.0 million in Q1 2023 and a floor of -$20.0 million in Q1 2022.